In this article, we will discuss Ofatumumab (Dosage Overview). So, let’s get started.
Previously Untreated Chronic Lymphocytic Leukemia
Ofatumumab is indicated, in combination with chlorambucil, for the treatment of previously
untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.
Extended Treatment in CLL
Ofatumumab is indicated for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.
Ofatumumab is indicated for the treatment of patients with CLL refractory to fludarabine and alemtuzumab.
Recommended Dosage Regimen
• Dilute and administer as an intravenous infusion according to the following schedules.
• Do not administer as an intravenous push or bolus or as a subcutaneous injection.
• Pre-medicate before each infusion.
Previously Untreated CLL: The recommended dosage and schedule is:
• 300 mg on Day 1 followed 1 week later by 1,000 mg on Day 8 (Cycle 1) followed by
• 1,000 mg on Day 1 of subsequent 28-day cycles for a minimum of 3 cycles until best response or a maximum of 12 cycles.
Extended Treatment in CLL: The recommended dosage and schedule as single-agent extended treatment in
• 300 mg on Day 1, followed by
• 1,000 mg 1 week later on Day 8, followed by
• 1,000 mg 7 weeks later and every 8 weeks thereafter for up to a maximum of 2 years.
Refractory CLL: The recommended dosage and schedule is 12 doses administered as follows:
• 300 mg initial dose on Day 1, followed 1 week later by
• 2,000 mg weekly for 7 doses (Infusions 2 through 8), followed 4 weeks later by
• 2,000 mg every 4 weeks for 4 doses (Infusions 9 through 12).